Can Assoc Gastroenterol. 2023 Jun 1;6(Suppl 2):S1-S8.doi: 10.1093/jcag/gwad003. eCollection 2023 Sep.

Joseph W Windsor ¹, M Ellen Kuenzig ^2 3, Sanjay K Murthy ^4 5, Alain Bitton ⁶, Charles N Bernstein ^7 8, Jennifer L Jones ⁹, Kate Lee ¹⁰, Laura E Targownik ¹¹, Juan-Nicolás Peña-Sánchez ¹², Noelle Rohatinsky ¹³, Sara Ghandeharian ¹⁰, James H B Im ^2 3, Tal Davis ^2 3, Jake Weinstein ^2 3, Quinn Goddard ¹, Eric I Benchimol ^{2 3 14 15 16}, Gilaad G Kaplan ¹

Author information

¹Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

²SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.

³Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.

⁴Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

⁵The Ottawa Hospital IBD Centre, Ottawa, Ontario, Canada.

⁶Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University, Quebec, Canada.

⁷Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

⁸University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.

⁹Departments of Medicine, Clinical Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.

¹⁰Crohn's and Colitis Canada, Toronto, Ontario, Canada.

¹¹Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

¹²Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

¹³College of Nursing, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

¹⁴ICES, Toronto, Ontario, Canada.

¹⁵Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

¹⁶Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Abstract

The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased since Crohn's and Colitis Canada's 2018 Impact of IBD report from an estimated 270,000 Canadians living with IBD in 2018 to an estimated 322,600 Canadians living with IBD today in 2023. Consequently, associated costs of IBD have also dramatically increased from an estimated $2.57 billion in 2018 to an estimated $5.38 billion in 2023; this increase is due to multiple factors including increased prevalence of disease, inflation, and additional identified factors (e.g., presenteeism, costs of childcare). Beyond the economic impact of IBD, these diseases have a significant impact on people living with the disease and their caregivers, including different presentations of disease, different commonly associated extra-intestinal manifestations or comorbid conditions, and different barriers to accessing care. In this supplementary issue, we review: Evolving trends in the epidemiology of IBD; updated estimates of indirect and direct costs (including out-of-pocket costs) associated with IBD; information specific to IBD in children, adolescents, and seniors; issues related to IBD pertaining to sex and gender; information specific to risks associated with COVID-19 and cancer related to IBD; an overview of current treatments for IBD; and evolving care models, including access to care.